CRMD — CorMedix Inc
NASDAQ · Healthcare · Biotechnology
$8.44
+$0.06 (+0.72%)
CorMedix Inc (CRMD) is a biotechnology company listed on NASDAQ. It is led by Joseph Todisco MBA, based in 389 Interpace Pkwy, Parsippany, NJ, United States, 07054, with about 191 employees. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Latest reported CRMD revenue for 2025-09-30 was $104.3M. Net income was $108.6M. Revenue was up 162.4% from 2025-06-30 to 2025-09-30. CRMD currently screens at market cap $655.9M and trailing P/E 3.9.
Use this CRMD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CRMD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CRMD SEC filings page. Lician reads the product cache first so this HTML stays unique to CorMedix Inc even when a live quote feed is slow.
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
CRMD Key Statistics
Market Cap
$655.86M
Volume
1.23M
Previous Close
$8.28
Day Range
$8.28 – $8.57
P/E Ratio
3.85
EPS
-$0.30
Revenue
$43.47M
Net Income
-$17.93M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-41.2%
Employees
191
CRMD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $43.47M | $0.00 | $65.41K | $190.94K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$17.93M | -$46.34M | -$29.70M | -$28.21M |
| EPS (Diluted) | -$0.30 | -$0.91 | -$0.74 | -$0.75 |
Total Assets
$118.85M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$40.65M
Operating Cash Flow
-$50.61M
Free Cash Flow
$0.00
CorMedix Inc Company Information
- CEO & Chairman of the Board of Directors
- Joseph Todisco MBA
- Headquarters
- 389 Interpace Pkwy, Parsippany, NJ, United States, 07054
- Website
- cormedix.com
- Phone
- 908 517 9500
- IPO / Founded
- 2010-03-25
- Sector
- Healthcare
- Industry
- Biotechnology